EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 130 filers reported holding EDGEWISE THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 1.01 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $114,263,184 | +72.0% | 6,344,430 | +4.5% | 6.63% | +61.7% |
| Q4 2023 | $66,424,431 | +90.9% | 6,071,703 | 0.0% | 4.10% | +59.5% |
| Q3 2023 | $34,790,858 | -26.1% | 6,071,703 | 0.0% | 2.57% | -29.3% |
| Q2 2023 | $47,055,698 | +16.2% | 6,071,703 | 0.0% | 3.64% | +36.1% |
| Q1 2023 | $40,498,259 | -25.4% | 6,071,703 | 0.0% | 2.67% | -21.2% |
| Q4 2022 | $54,281,025 | -9.1% | 6,071,703 | 0.0% | 3.39% | +19.0% |
| Q3 2022 | $59,746,000 | +34.3% | 6,071,703 | +8.7% | 2.85% | +30.1% |
| Q2 2022 | $44,474,000 | -17.9% | 5,587,207 | 0.0% | 2.19% | -23.4% |
| Q1 2022 | $54,196,000 | -36.5% | 5,587,207 | 0.0% | 2.86% | -29.3% |
| Q4 2021 | $85,373,000 | -8.0% | 5,587,207 | 0.0% | 4.04% | -15.7% |
| Q3 2021 | $92,748,000 | -22.2% | 5,587,207 | 0.0% | 4.80% | -9.3% |
| Q2 2021 | $119,175,000 | -34.4% | 5,587,207 | 0.0% | 5.29% | -29.5% |
| Q1 2021 | $181,584,000 | – | 5,587,207 | – | 7.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |